Swedish Orphan Biovitrum 将来の成長

Future 基準チェック /46

Swedish Orphan Biovitrum利益と収益がそれぞれ年間20.1%と8.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に12.8% 20.6%なると予測されています。

主要情報

20.1%

収益成長率

20.6%

EPS成長率

Biotechs 収益成長	49.5%
収益成長率	8.9%
将来の株主資本利益率	12.8%
アナリストカバレッジ	Good
最終更新日	01 Nov 2024

今後の成長に関する最新情報

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Oct 27

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 19

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 27

Recent updates

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Oct 27

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 19

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Jun 24

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

May 08

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 27

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Apr 24

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 06

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Mar 05

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 15

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Jan 17

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

Dec 27

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Sep 28

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Jun 26

業績と収益の成長予測

OM:SOBI - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	31,284	6,544	9,118	9,553	10
12/31/2025	27,839	4,882	7,306	7,853	11
12/31/2024	25,430	3,459	5,945	5,924	9
9/30/2024	25,435	3,514	3,255	6,663	N/A
6/30/2024	23,710	2,145	5,056	6,716	N/A
3/31/2024	23,140	2,142	2,313	4,743	N/A
12/31/2023	22,123	2,409	-473	4,470	N/A
9/30/2023	21,270	2,769	743	5,291	N/A
6/30/2023	20,100	3,125	120	4,977	N/A
3/31/2023	19,104	3,162	337	4,915	N/A
12/31/2022	18,790	2,638	3,099	4,576	N/A
9/30/2022	17,696	2,493	3,145	4,804	N/A
6/30/2022	17,458	2,516	3,363	4,317	N/A
3/31/2022	16,793	2,526	4,979	5,415	N/A
12/31/2021	15,529	2,679	5,100	5,470	N/A
9/30/2021	15,214	2,940	1,405	4,066	N/A
6/30/2021	14,424	2,744	378	4,190	N/A
3/31/2021	14,283	2,759	819	4,739	N/A
12/31/2020	15,261	3,245	1,074	4,926	N/A
9/30/2020	15,570	3,103	3,101	5,185	N/A
6/30/2020	15,530	3,367	5,747	5,799	N/A
3/31/2020	15,622	3,583	5,176	5,132	N/A
12/31/2019	14,248	3,304	-5,171	3,634	N/A
9/30/2019	11,929	2,539	-4,868	3,195	N/A
6/30/2019	11,313	2,620	-6,526	2,912	N/A
3/31/2019	10,440	2,806	-7,233	2,201	N/A
12/31/2018	9,139	2,418	1,512	2,090	N/A
9/30/2018	8,443	2,181	1,217	1,810	N/A
6/30/2018	7,729	1,881	N/A	1,678	N/A
3/31/2018	7,079	1,462	N/A	1,287	N/A
12/31/2017	6,511	1,149	N/A	1,333	N/A
9/30/2017	5,927	865	N/A	1,103	N/A
6/30/2017	5,497	677	N/A	604	N/A
3/31/2017	5,327	703	N/A	431	N/A
12/31/2016	5,204	802	N/A	343	N/A
9/30/2016	4,727	716	N/A	329	N/A
6/30/2016	4,341	585	N/A	493	N/A
3/31/2016	3,636	291	N/A	573	N/A
12/31/2015	3,228	65	N/A	507	N/A
9/30/2015	3,119	59	N/A	547	N/A
6/30/2015	3,000	108	N/A	426	N/A
3/31/2015	2,899	136	N/A	268	N/A
12/31/2014	2,607	-268	N/A	234	N/A
9/30/2014	2,513	-263	N/A	185	N/A
6/30/2014	2,364	-373	N/A	86	N/A
3/31/2014	2,221	-410	N/A	189	N/A
12/31/2013	2,177	-93	N/A	185	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SOBIの予測収益成長率 (年間20.1% ) は貯蓄率 ( 1.2% ) を上回っています。

収益対市場: SOBIの収益 ( 20.1% ) はSwedish市場 ( 15.4% ) よりも速いペースで成長すると予測されています。

高成長収益: SOBIの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: SOBIの収益 ( 8.9% ) Swedish市場 ( 0.04% ) よりも速いペースで成長すると予測されています。

高い収益成長: SOBIの収益 ( 8.9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SOBIの自己資本利益率は、3年後には低くなると予測されています ( 12.8 %)。

Swedish Orphan Biovitrum 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Consensus EPS estimates increase by 21%

Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Recent updates

Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair

Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025

Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025

General Counsel & Head of Legal Affairs recently sold kr27m worth of stock

Investor sentiment improves as stock rises 15%

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

CEO & President recently sold kr29m worth of stock

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 21%

Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024

Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A

Head of North America recently sold kr37m worth of stock

CEO & President recently sold kr30m worth of stock

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings released: EPS: kr2.35 (vs kr3.60 in 1Q 2023)

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold kr5.7m worth of stock

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Senior Scientific & Medical Advisor recently sold kr16m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Independent Director recently bought kr439k worth of stock

New minor risk - Shareholder dilution

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Independent Director recently bought kr439k worth of stock

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

Head of International recently sold kr386k worth of stock

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Independent Chairman recently bought kr11m worth of stock

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Head of Europe recently sold kr15m worth of stock

CEO & President recently sold kr24m worth of stock

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023

Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well